MedTrace Logo

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

NCT01074632 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-09-08

No results posted yet for this study

Summary

The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.

Conditions

  • Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

Interventions

DRUG

Lurasidone HCl

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Primary Completion
2009-09-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01074632 on ClinicalTrials.gov